INS and obesity due to melanocortin 4 receptor deficiency: This provides insights into LEAP2 being used as a therapeutic agent for insulin secretion in type 2 diabetes and obesity as LEAP2 most likely directly increases insulin production rather than insulin sensitivity [70].